Abstract
Phase I study of immunotherapy with methanol extraction residue of BCG (MER) administered by the intravenous (IV) route
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have